Stock Ticker

  • Loading stock data...

LifeVantage Handles CFO Transition Deftly While Facebook’s Stock Continues to Suffer (LFVN) (FB)

David Ebersman, Chief Financial Officer of Facebook (NASDAQ: FB), is being touted as the man behind the flawed Facebook IPO that took the market by storm three months ago. While the blame game is being played in the Facebook IPO debacle, penny stock companies like LifeVantage (OTCQB: LFVN) are handling CFO changes without any controversy. David Colbert is the man chosen to be the company’s new CFO. LifeVantage’s current CFO, Carrie McQueen, has decided to not move to Utah with the company and has signed off on her position to Colbert who has worked with Standard & Poor’s 500 companies in the past.

Facebook IPO Debacle

The market very much anticipated the Facebook IPO. One of the biggest IPO’s ever, this release has also been called one of the worst mistakes of 2012. Over the last three months, the company has lost more than $50 billion in market value. The blame game is not something new in the market and the man whose head is about to roll is the CFO of Facebook, David Ebersman.

Company insider Andrew Ross Sorkin has clearly stated, “If there is one single individual more responsible than any other for the staggering mis-pricing of Facebook’s I.P.O., it is Mr. Ebersman.” Many analysts such as Sorkin believe that Ebersman’s decision to flood the market with 25% more shares than the amount that was initially planned for release is one of the reasons why the company’s IPO has failed so dismally.

When it comes to hot IPO’s like Facebook, it is common knowledge that investors put in a request for twice or thrice the amount of shares that they actually expect to buy. As CFO, this is something that Ebersman should have known and anticipated, but he clearly failed to do so. After releasing at a hefty $38 per share, the stock value has dramatically decreased to reach $17.72 as of September 4, 2012. It has been widely acknowledged that the company is not a great investment opportunity as of right now. Its business model is flawed and some say it really does not have one. Well, that was explained in The Social Network when it seemed the CEO, Mark Zuckerberg, did not seem too interested in making any money.

LifeVantage’s Advantage

A fabulous penny stock company such as LifeVantage, on the other hand, is being touted as one of the hottest stocks to buy over the counter. LifeVantage is a market leader in manufacturing dietary supplements. Its share value has only increased in recent times and it has reached $3.01 as of the September 4, 2012. Considering the fact that this is a high-volume common stock, it is doing well and is being called one of the best companies to invest in if you are dabbling in the OTC market.

International Reach

While Facebook is a social media networking platform that reaches people all over the globe, LifeVantage is also making its presence known in countries like India by contributing to the improvement of health and education for children in India. You cannot say anything bad about that.

Stocks to Invest In

Penny stocks, certainly LifeVantage and Talon Therapeutics (OTCQB: TLON), which is a biopharmaceutical company, offer better investment opportunities for individuals interested in high-volume trading. Facebook may have a big name and be a social media titan, but it is being “unfriended” quickly.

Published by Benjamin Roussey

Benjamin Roussey is from Sacramento, California. He has two master’s degrees and served four years in the U.S. Navy. His bachelor’s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master’s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http://www.facebook.com/ben.rouss



  • Recent Stories

    SignUp Now For Our Featured Newsletter

    Sign Up To Get Our Latest Stocks Alerts